Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

Also called NCT02172040

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 152 participants (enrolled count) (from the registry)
Sponsor
Kitov Pharmaceuticals, Ltd. (from the registry)
Registry
  • NCT NCT02172040
  • EudraCT 2013-005381-19
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02172040. Randomized; triple masking; primary purpose treatment. Start 2014-06-26 (actual); primary completion 2015-11-19 (actual). Results posted on 2017-10-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
Condition
Hypertension
Intervention (Drug)
Over-encapsulated 10 mg amlodipine besylate tablet
Intervention (Drug)
Matched placebo capsule for over-encapsulated celecoxib capsule
Intervention (Drug)
Over-encapsulated 200 mg celecoxib capsule
Intervention (Drug)
Matched placebo capsule for over-encapsulated amlodipine besylate tablet
Lead sponsor
Kitov Pharmaceuticals, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02172040
Content hash
6e803c5b77634947d66313598e30b3b1c3dc50a833ab4eab1e2ac4332b628cde